Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 42,964

Document Document Title
WO/2020/187865A1
The invention relates to compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.  
WO/2020/190119A1
The present invention relates to a 6-(isooxazolidin-2-yl)-N-phenylpyrimidin-4-amine derivative, and a pharmaceutical composition for preventing or treating cancer comprising the compound as an effective component. The compound exhibits h...  
WO/2020/187165A1
The present invention falls within the technical field of medicine, and in particular relates to a crystal form of a phosphodiesterase inhibitor as shown in formula (I), a preparation method therefor and the use thereof.  
WO/2020/190754A1
The invention relates to modulators of Embryonic Ectoderm Development (EED) and/or Polycomb Repressive Complex 2 (PRC2) useful in the treatment of disorders and diseases associated with EEC and PRC2, being macrocyclic azolopyridine deriv...  
WO/2020/191207A1
The invention provides therapeutic combinations and therapeutic methods that are useful for treating Hepatitis B and Hepatitis D.  
WO/2020/187267A1
The present invention provides a BTK inhibitor, a pharmaceutically acceptable salt, a polymorph and an application thereof. Specifically, the present invention provides (R)-6-((1-Acryloylpiperidin-3-yl)amino)-7-fluoro-4-((2-fluor o-4-mor...  
WO/2020/191261A1
The present invention is directed to indazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.  
WO/2020/189576A1
[Problem] A crystal of a heterocyclic amide compound and a method for producing same [Solution] It has been shown that a heterocyclic amide compound, which is a compound having useful activity as a herbicide, has a novel crystal, as expr...  
WO/2020/186291A1
The present invention provides compounds that modulate biological metals and to pharmaceutical compositions containing such compounds. The invention particularly relates to imidazo[1,5-a]pyridine compounds that modulate iron and are usef...  
WO/2020/188049A1
The present invention relates to compounds of the general formula (I): (I), wherein V, W, M, R, R and Y have the designations cited below, or a pharmaceutically or veterinary acceptable salt, hydrate or solvate thereof, and to processes ...  
WO/2020/191047A1
Disclosed herein are GABAA receptor modulators and compositions comprising GABAA receptor modulators for treatment of pain and associated conditions such as fibromyalgia. Also disclosed herein are methods of treating pain and associated ...  
WO/2020/190792A1
Pharmaceutical compositions comprising a CBP Inhibitor compound can be used to treat patients diagnosed with Androgen Receptor positive forms of cancer, such as mCRPC and TNBC, including patients diagnosed with the AR-v7 splice form.  
WO/2020/187123A1
Disclosed are a pyrrole amidopyridone represented by general formula I, or a pharmaceutically acceptable salt thereof, or an enantiomer, a diastereomer, a tautomer, a solvate, a polymorph, or a prodrug thereof, a preparation method there...  
WO/2020/190791A1
The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For inst...  
WO/2020/185812A1
The present disclosure relates to solid state forms of ripretinib, processes for preparation thereof, as well as a pharmaceutical composition including the same.  
WO/2020/068304A3
Compositions and methods for inhibiting the activity of RNA-guided endonucleases, and methods for identifying such compositions are included. Methods of treatment using the inhibitory compounds, formulations and methods are also detailed...  
WO/2020/182990A1
The present application relates to compounds according to Formula (I), pharmaceutical compositions comprising at least one of said compounds, their use as a medicament, and their use in treating chronic hepatitis B virus (HBV) infection....  
WO/2020/184670A1
The present invention relates to a method for monodeuterated lower alkylating an amine moiety of a compound which contains an amine that is protected by an aralkyl group, wherein a monodeuterated lower alkyl is introduced into the amine ...  
WO/2020/185044A1
The present invention relates to a heteroaryl derivative and a pharmaceutical composition for the prevention or treatment of cancer comprising same as an active ingredient, and a compound according to an aspect of the present invention, ...  
WO/2020/182978A1
The present invention relates to crystalline lumateperone naphthalene-1,5-disulfonic acid addition salt and a process for its preparation. The invention also relates to a pharmaceutical composition comprising crystalline lumateperone nap...  
WO/2020/185729A1
A crystalline form of an avibactam derivative (1), i.e. crystalline ethyl 3-(((((1R,2S,5R)-2-carbamoyl-7-oxo-l,6-diazabicyclo[3.2.1]oc tan-6-yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate anhydrate (I), pharmaceutical compositions thereof, ...  
WO/2020/186006A1
This application is directed to inhibitors of RAD51 represented by the following structural formula, (I), and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.  
WO/2020/186027A1
Tri-cyclyl nitrogen-containing heterocyclic compounds are disclosed. The compounds are inhibitors of human cGAS in interferon-producing cell types. They are thus useful as therapeutic agents for treating cGAS-related autoimmune diseases ...  
WO/2020/183307A1
The present invention is directed to various 3',4'-dihydro-2'H-spiro[indoline-3:1'-isoquinolin]-2-one compounds and methods for treating disease states and/or conditions which are mediated through sphingosine-1-phosphate receptor(s). The...  
WO/2020/182577A1
Compounds of the formula (I) wherein the substituents are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compositions, and t...  
WO/2020/182062A1
The present invention relates to an FGFR4 kinase inhibitor, a preparation method therefor and use thereof. The present invention relates to a compound of formula I, or a pharmaceutically acceptable salt, solvate, polymorph or isomer ther...  
WO/2020/184578A1
Provided is a novel elF2α phosphorylation promoter that is a compound represented by general formula (1) or a pharmaceutically acceptable salt of said compound. In the formula, R1 is a substituted or unsubstituted aryl group, a substitu...  
WO/2020/154519A3
The invention relates to particular substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, for use in meth...  
WO/2020/182159A1
Related are a JAK kinase inhibitor, a preparation method for same, and applications thereof in the field of medicine, related to the field of medicinal chemistry. Provided is a novel small molecule JAK inhibitor, which has the structure ...  
WO/2020/177653A1
The present invention relates to a pyrazine derivative, an application thereof in inhibiting SHP2, and a compound of formula (I) or pharmaceutically acceptable salts, esters, isomers, solvates, prodrugs or isotope labels thereof. The str...  
WO/2020/181026A1
The present invention relates to novel substituted aromatic-aliphatic amines capable of penetrating blood brain barrier and mediating pathogenic process in neurodegenerative diseases.  
WO/2020/177629A1
Disclosed are a spiro-substituted pyrimidine-fused cyclic compound represented by Formula I or Formula II and pharmaceutically acceptable salts, stereoisomers, solvent compounds or prodrugs thereof. The compound has a selective inhibitor...  
WO/2020/180768A1
The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.  
WO/2020/157652A3
This invention relates to compounds of Formula (I), and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to phar...  
WO/2020/176983A1
The present application relates to novel compounds of Formula (I) containing a E3 ubiquitin ligase binding moiety linked to a Raf protein kinase binding moiety. The present application also includes methods and uses of the compounds, for...  
WO/2020/178316A1
The present invention relates to β-lactamase inhibitors having the following general formula (I): wherein R1-R4 and X1-X2 are defined in the specification, pharmaceutical composition thereof, and use thereof for the treatment of a bacte...  
WO/2020/178267A1
The present invention relates to a NOX inhibitor compound of formula (I), preferably a NOX2 inhibitor, and a pharmaceutical composition comprising such compound, for use for preventing an epileptic seizure. The invention further concerns...  
WO/2020/177715A1
The present invention belongs to the field of medicine, and relates to an influenza virus replication inhibitor and a use thereof, and provided thereby are a novel compound as an influenza virus replication inhibitor and a preparation me...  
WO/2020/127208A3
The present disclosure concerns the large-scale manufacture of pharmaceutical compounds, and novel intermediates for use in the manufacture. International Patent Application WO2011154737 discloses morpholine pyrimidines useful for treati...  
WO/2020/178434A1
The present invention relates to a process for synthesizing N-(4-(4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1 -yl)butyl)-N-(tetrahydro-2H-pyran-4-yl)acetamide of formula (I), an imidazoquinoline derivative useful as toll-like ...  
WO/2020/177668A1
The present invention relates to pyrazolo[1,5-a]pyridine derivatives, a preparation method therefor and a medical application thereof. In particular, the present invention relates to pyrazolo[1,5-a]pyridine derivatives represented by gen...  
WO/2020/178175A1
The invention relates to a method for producing 4-amino-5-methyl-2(1H) pyridone of the formula (I) by reacting 2-chloro-5-methyl-4-pyridinamine of the formula 2 with KOH in methanol in a pressure reactor and to a method for producing 2-c...  
WO/2020/177658A1
Disclosed in the present application are a method for preparing a tricyclic compound, and an intermediate thereof, and in particular, a method for preparing (3S,3aR)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-pyrazolo[3,4-f ]quinolone compound...  
WO/2020/177705A1
A new Filgotinib maleate crystal form, a preparation method therefor, a pharmaceutical composition containing said crystal form, and use of the crystal form in the preparation of a JAK selective inhibitor and pharmaceutical formulations ...  
WO/2020/174283A1
Provided herein are methods for treating endometriosis, endometriosis-associated pain, and endometriosis-associated symptoms in a mammal in need thereof with a P2X3 modulator.  
WO/2020/173861A1
The invention relates to novel compounds of formula (I), in which Aa, Ab, Ac, Ad, Ae, Q, R1 and n are defined as in the description, to the use thereof as acaricides and/or insecticides for controlling animal pests, and to processes and ...  
WO/2020/176610A1
One aspect described herein includes a method for treating a multiple myeloma (MM) in a subject in need thereof comprising, administering to the subject an effective amount of a small molecule compound. More particularly, another aspect ...  
WO/2020/173364A1
The present invention relates to an oral pharmaceutical composition with an azetidine derivative as an active ingredient, and a preparation method therefor and the use thereof. The preparation process of the oral pharmaceutical compositi...  
WO/2020/176654A1
Use of caseinolytic protease P (ClpP) function and/or concentration as a biomarker for predicting the response of a neoplastic disease, preferably cancer or another disease where enhancing ClpP activity may provide a therapeutic benefit,...  
WO/2020/176599A1
The present invention provides azepino-indoles and other heterocycles and methods of using the compounds for treating brain disorders.  

Matches 1 - 50 out of 42,964